Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism (August 24, 2026 ) by James Waldron Roche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage UCN2 (urocortin-2) analog from South Korea’s Hanmi Pharm. UCN2 is a signaling protein that is elevated in people with chronic heart failure. The
By Ross Youngs, August 31, 2026 The Ghost Genome: Mapping a Constrained Chemical Execution Layer of Human Biology Abstract Genomics maps biological capacity but does not directly report the real-time chemistry produced when host and microbial genes, viruses, diet, medicines, anatomy, environment, and time interact. Here, the ghost genome is a temporary working name for the unknown or under-characterized portion
